Foreword
Five year R&D plans
are developed for each of RIRDC’s major programs. The present plan (2006-2011)
is the second R&D Plan for the Tea Tree Oil Program.
The first plan covered the
period 1998-2003 and was used to guide the program up until August 2005.
The 2006-2011 plan identifies
four key objectives for the R&D investments to be made on behalf of
the industry and Australian Government.
Associated with each objective
is a set of strategies to be followed in pursuing each objective and a
set of performance indicators to give guidance as to how the program can
be assessed as it progresses.
This Plan has been prepared
by RIRDC’s Tea Tree Oil Research and Development Advisory Committee. The
development of the Plan has received input from
both growers and product
manufacturers during August and September 2005. It is the most recent R&D
planning initiative following a planning conference in 1989,
the establishment of the
program in 1990, a marketing and planning conference in 1991, a review
of the program in 1994 and the first Five Year R&D Plan
developed in 1998 through
consultation with industry members and other stakeholders.
The Plan reflects the state
of the industry in 2005. A decline in the price of tea tree oil since the
last Plan and the development of significant new regulatory barriers have
meant that some of the future R&D directions have changed to those
developed in 1998. However, other priorities remain pertinent, particularly
in the area of increasing the demand for oil in the long term, and maintaining
Australia’s competitive advantage through the breeding project.
This Plan is consistent with
the RIRDC Corporate Plan (2003-2008) and will be implemented in accordance
with the provisions of the Primary Industries and Energy Research and Development
Act 1989.
Peter
O’Brien
Managing Director
Rural Industries Research
and Development Corporation |
Pat Bolster
Chairperson
Rural Industries Research
and Development Corporation
Tea Tree Oil R&D Advisory
Committee |
Snapshot
of the Five Year Plan
Goal
To support the continued
development of a profitable and environmentally sustainable Australian
tea tree oil industry that has established international leadership in
marketing, value adding, product reliability and production.
Objectives
Enhancing production systems
to maintain the competitiveness of Australian growers.
Identifying regulatory regimes
and market barriers, and enhancing the ability of industry to meet safety
standards.
Demonstrating proof of concept/efficacy
for innovative applications of tea tree oil.
Fostering communication that
increases understanding and thereby encourages greater use of tea tree
oil.
|
1. Purpose
of the Plan
The purpose of this Five
Year Plan is:
To present the rationale and
context for R&D required in the tea tree oil industry,
To indicate the specific role
that RIRDC funded R&D will play in expanding the knowledge base of
the industry, and improving its profitability and sustainability,
To outline the broad priorities
that RIRDC will pursue through its investment in the program over the next
five years,
To take account of national
research priorities, Ministerial guidance and RIRDC policies, and
To encourage collaboration and
coordination for tea tree industry R&D, including new joint investment.
The plan is based on consultation
with industry via a survey of industry members including growers, manufacturers
and traders during July 2005, as well as a workshop involving the RIRDC
R&D Advisory Committee and other industry representatives held in August
2005. A draft plan was presented at the Industry Symposium in Wollongbar
in September 2005 and refined following feedback from those that attended.
2. Industry
Profile
Tea tree oil has been produced
and marketed in Australia since the 1920s. Although the industry was first
based on bush cutting, most commercial production is now sourced from the
cultivation of Melaleuca alternifolia, predominantly grown in the
coastal region of northern New South Wales and the Atherton Tablelands
of Queensland.
There are currently around
4,500 ha of cultivated tea tree growing in these locations in Australia
and there are currently about 100 growers. Biomass and oil yields vary
significantly from plantation to plantation and within plantations. In
2004/05, 517 tonnes of tea tree oil were produced and 527 tonnes sold.
The Australian Tea Tree Industry Association (ATTIA) is the peak industry
body.
The oil is extracted by steam
distillation from the mechanically harvested aboveground portion of the
plant material. The major parameters of the oil are described by the international
standard ISO 4730-2004.
There have been strong market
forces operating over the past seven years. Production peaked at an estimated
7-800 tonnes in 1999/2000. Prices fell from a high of $50,000/tonne in
1997/8 to $1,200/tonne in 2004. Currently the price has climbed to $15,000/tonne.
As a result of over-production, growers left the industry in the period
2001-3 and production fell to an estimated 300-400 tonnes, some oil being
held in stock in the expectation of rising prices. As stocked oil was sold
into the marketplace, real demand became evident and production followed
suit, rising to over 500 tonnes in 2004/5. Prices have risen with the increase
in demand.
According to the Industry
Stock and Production Audit, demand has shown an increase of 25% (2003/04)
and 13% (2004/05) per annum for each of the past two years. This growth
is despite a fall in generic promotional activity by the industry for 6
to 7 years. The demand figures have been derived as a function of stock
changes and estimated production.
The market for tea tree oil
in the cosmetic and personal health areas is maturing with the oil no longer
being sought for its novelty value. Most oil is still sold in pure form
and used for various purposes due to its anti-bacterial, anti-fungal, anti-viral
and anti-inflammatory properties. Small quantities of oil are included
in a very wide range of personal health care, cosmetic and animal care
products. There is also one rural industrial use of tea tree oil now commencing
and at least two known pending industrial uses. About 90% of Australian
tea tree oil is exported, principally to North America and Europe.
On the supply side, the capacity
of the industry to produce has been largely maintained. Various factors
influence oil production in any year including climatic factors, oil prices
and fertiliser practices. Production of oil has increased significantly
in the past two years to around 550 tonnes per annum.
Over the past eight years
there has been enough improved seed sold from the breeding program to plant
around 1,000 hectares of tea tree. Most of these sales occurred four to
eight years ago with less occurring in the past four years due to a downturn
in the industry. However, this year there has been a marked increase in
seed purchases following an improvement in market conditions and an even
higher yield potential from the most recently released seed.
Overseas production is currently
small but speculation is still manifest on low labour-cost countries in
Asia and Africa developing tea tree oil production. The current low international
price for oil is probably slowing any expansion in tea tree oil production,
as in Australia. However, if the price and/or demand were to increase,
there is the potential for overseas countries to increase production with
some speed.
3. Key Challenges
for the Industry
The strengths of the industry
include:
Australia has a highly capable
production sector equipped with knowledge of best management and sustainable
practices
The industry is supported by
a skilled and diverse human resource base
There is an established peak
industry body
There is an established research
infrastructure and R&D program
Australia is the current leader
in the world production of oil
Australia has the capacity to
lift production quickly if demand improves to limit high prices attracting
overseas supply
Australia has available higher
yielding seed to reduce costs of production and a breeding program to provide
continuous improvement
Oil extraction is clean, simple,
relatively inexpensive and produces little waste
The oil has proven in vitro
efficacy against certain micro-organisms
The oil has versatility in end-use
and capacity for value-adding
Tea tree oil is a natural product
that enjoys a "clean and green" reputation
The oil is described by an international
standard
The regulatory system in Australia
classifies tea tree oil as a therapeutic good
There is a growing market for
tea tree trash for mulch
Tea tree oil is non-perishable
and does not need secondary processing
The weaknesses of the industry
are:
The present price of oil is
not as profitable as the previous higher prices
The capital base of the industry
is being eroded through non-replacement strategies
Current demand is largely dependent
on pure oil sold in bottles and this level of concentration may face safety
and toxicity market challenges in the future
Tea tree oil has lost its prestige
and novelty values due to the abundance of oil, the associated price fall,
and its changed position in the product life cycle
The industry is fragmented with
differing agendas
There is a piecemeal approach
to marketing and consistent market intelligence is lacking
Communication within the industry
is not always good
Product knowledge is limited
Information on formulation is
limited
A distinctive Australian quality
branding is lacking
Regulatory approval is still
lacking for key target markets
There are gaps in the safety
profile for tea tree oil
Efficacy data is limited, particularly
from clinical trials
The smell of the oil is objectionable
to some
Opportunities facing the industry
are:
Australian production can become
the lowest cost producer in the world
Australian tea tree oil can
be established as the premier brand
Oil quality grading and descriptions
can be established based on real attributes
Demand can be enhanced through
further market development based on the efficacy of tea tree oil against
a range of microbes
Increased demand is potentially
available in the areas of antifungals (health care, biocides and agriculture)
and in hospitals against MRSA (Golden Staph)
Improved and new formulations
can be developed
The reduced prices are opening
up opportunities in other market segments
The price fall will lower costs
of production of oil through changed management practices and the departure
of higher cost producers
The improved higher yielding
seed becoming available will allow even lower costs of production
The current interest in and
demand for natural products can be capitalised on
The "clean and green" perception
can be exploited and an image of scientifically-backed products can be
created
Industry consultation and planning
processes can be improved, thereby increasing support for promotion, quality
standards and R&D
Threats facing the industry
are:
Cost inflation is driving up
costs of production (eg. increasing fuel prices)
The oil may be excluded from
some markets due to stricter regulatory regimes based on safety and toxicity
factors
There is ready availability
of substitute ingredients when the oil is providing no real functional
benefits and when safety is an issue
Low cost production of oil is
possible in low labour cost countries
There are competing natural
products
There can be leakage of improved
genetic material to overseas competitors
There is competition and pressure
from the pharmaceutical industry
There may be changes to the
safety and efficacy regulatory environment
The key challenge for the industry
is to increase demand and improve profitability. The latter is already
being sought by industry on the supply side through lowering costs of production
as far as possible using improvements to production methods. The yield
from the improved seed offers significant potential for lowering costs
in the future if sufficient incentive for new or replacement plantings
eventuate.
Reducing costs of production
is not only important as a potential contributor to restoring profitability
but also to maintaining Australia’s competitive advantage against the rest
of the world.
The challenge on the demand
side is to identify new markets or enhance existing markets that will require
large quantities of oil. This will require a long-term approach with continued
seed funding to demonstrate the oil’s capability and stimulating research
by others. It will be necessary to demonstrate to potential users and regulatory
authorities that tea tree oil is safe and effective. This will require
a high level of communication to potential users and authorities as well
as the development of new information regarding the impact of tea tree
oil.
4. Research
Directions
The past Five Year Plan
(1998-2003) has recently been reviewed. The conclusions from that review
are:
There were significant indirect
impacts of R&D findings through supporting proprietary efforts and
the lead and focus provided by the program’s R&D. Progress in the areas
of market and product development associated with tea tree oil has not
been as rapid as hoped by industry.
Some manufacturers were unaware
of the research program. Communication of research reports targeted to
these and other manufacturers and product developers should be enhanced.
This could take the form of concise summaries of major findings and the
provision of contact details of where follow-ups can be made. Such information
could be sent out by email.
An increased knowledge of efficacy
and toxicity has been produced from the R&D program. This is useful
for addressing current regulatory concerns and those that may arise in
the future. Further assessment is necessary to define the most constraining
regulatory barriers and concerns that may limit opportunities for increasing
the demand for tea tree oil.
The role of the program is to
support product and market development through strategic and generic R&D
activities, rather than directly supporting the development and commercialisation
of products. Product development is at the other end of the process of
increasing demand. This should be made clearer to industry.
The increased yields apparent
from the improved seed produced from the breeding program (90% improved
yield) has significant potential to lower the costs of production. The
low profitability from the oil and the costs of replanting or planting
new areas of tea tree has limited this impact. However, there is considerable
support for the breeding program to continue in the long term. The difficulties
of closing the program down and then regenerating it at some future time
need to be recognised.
Some key directions for R&D
for the next five years are:
The program should enhance its
focus on consolidating and disseminating available information on tea tree
oil to both Australian and overseas manufacturing and product development
interests.
The program should continue
to support studies that demonstrate the efficacy of tea tree oil.
The program should continue
to support R&D in the area of product safety.
To make best use of scarce R&D
resources such studies should be prioritised carefully by considering
(i) the likely market sizes
that exist for different oil uses
(ii) the ease of surmounting
associated regulatory barriers, and
(iii) some informed opinion
of the chances of success of producing information that will make a difference
to regulatory barriers and to market penetration and development.
Further developing the position
of Australian tea tree oil in the market place as a high quality and reliable
oil will be an important underpinning strategy for the Industry.
Reducing costs of production
is an important component of returning the industry or at least part of
the industry to high levels of profitability. In this regard the breeding
program is a valuable asset of the industry requiring protection, potentially
through Plant Breeders Rights.
This plan is consistent with
the RIRDC goals of developing new opportunities and markets for agricultural
products, improving competitiveness and sustainability, and generally supporting
innovation and change in Australian agriculture. The plan also supports
RIRDC strategies that have been developed to address the national and rural
research priorities set by the Australian Government through:
promoting demand for safe and
healthy products
commercialising new products
maintaining confidence in the
integrity of Australian products
Tea tree oil is increasingly
being recognised as a commodity that has the potential for use in a wide
range of sectors other than the traditional anti-microbial and personal
health care uses that have largely been researched and pursued as markets.
Alternative markets include the agricultural sector (as a fungicide and
pesticide); the health sector (to control outbreaks of MRSA); biocidals
(everyday cleaning and disinfectant agents); and industrial uses such as
air conditioning decontamination. These markets are now being pursued by
product developers – in some cases the products are already available in
the market place.
While the profitability of
the industry has been low, funds for R&D from the tea tree oil production
sector have not been significant. Therefore alternative avenues for R&D
funding have been pursued from the above sectors. This strategy is likely
to continue, with funds being sought from growers for the breeding project
and funds towards the other objectives being sought from processors, product
developers and relevant companies.
The R&D program largely
focuses its research in the early stages of the product development chain.
It can not realistically be expected that outcomes in the form of commercialisation
and sales of products attributable to the research can always be achieved
within the life of the R&D program.
The performance indicators
developed in the R&D plan reflect this, by focusing on measuring outputs
and early stage outcomes.
5. The Research
and Development Program 2006-2011
Goal
Objective 1: Enhancing
production systems to maintain the competitiveness of Australian growers
*
Strategies
Performance
Indicators
Objective 2: Identifying
regulatory regimes and market barriers, and enhancing the ability of industry
to meet safety standards
Strategies
Performance
Indicators
Objective 3: Demonstrating
proof of concept/efficacy for innovative applications of tea tree oil *
Strategies
Performance
Indicators
Objective 4: Fostering
communication that increases understanding and thereby encourages greater
use of tea tree oil *
Strategies
Performance
Indicators
Goal
To support the continued
development of a profitable and environmentally sustainable Australian
tea tree oil industry that has established international leadership in
marketing, value adding, product reliability and production.
Objective
1:
Enhancing production systems to maintain the competitiveness of Australian
growers
Strategies
Ensure the competitiveness of
the Australian tea tree growers through providing high yielding varieties
of tea tree.
Ensure that improved seed is
protected to retain the competitive advantage of Australian growers.
Support the code of practice
and logo for the Australian tea tree oil industry with the purpose of maintaining
international recognition of Australian certified oil as a quality and
reliable product.
Identify and research by-products
of tea tree oil production to ensure a diverse range of products from the
production system (for example, use of farm waste for co-generation).
Develop the capital of the industry
by developing training packages for the code of practice and enforcing
the standard.
Performance
Indicators
Breeding Program continued with
the objective of achieving an oil yield gain of 120% by 2007/8 and 150%
by 2010/11 in the orchards and 150% by 2007/8 for the clones.
Seed sales to industry of 375g
seed per year (i.e sufficient to plant 100ha/yr)
Yield increase demonstrated
in plantings of producers of up to 120% by 2007/8 and 150% by 2010/11
Protection for improved seed
(possibly via Plant Breeders Rights or DNA Fingerprinting)
Logo and code of practice taken
up by industry.
Objective
2: Identifying regulatory regimes and market barriers, and enhancing
the ability of industry to meet safety standards
Strategies
Undertake studies to identify
expected regulations for a range of products including traditional medicine,
cosmetics, biocidal, industrial and agricultural uses.
Identification of priorities
for overcoming regulatory barriers which are constraining or likely to
constrain in the future, the demand for tea tree oil.
Fund R&D, synthesis and
communication activities that address existing or potential regulatory
barriers.
Undertake generic safety and
toxicology studies to meet regulatory requirements for a range of potential
uses of tea tree oil.
Disseminate generic safety data
to manufacturers to ensure appropriate handling and use of tea tree oil.
Performance
Indicators
Evidence of actual or potential
regulatory barriers identified and prioritised.
Evidence of addressing, ameliorating,
delaying or removing actual or potential regulatory barriers.
Additions to the knowledge bank
of the safety of tea tree oil that is relevant to regulatory authorities.
Examples of actions taken by
manufacturers and marketers to improve the safe use of tea tree oil.
Objective 3:
Demonstrating proof of concept/efficacy for innovative applications of
tea tree oil
Strategies
Identify and support innovative
proof of concept/efficacy projects - including those in the areas of agriculture,
industrial, cosmetic, biocidal and anti-microbial uses.
Actively encourage and target
manufacturers to use research findings and develop them further to the
product stage. Develop methods for targeting such individuals and companies.
Prepare and disseminate guidelines
for formulations to ensure researchers and product developers are using
the appropriate formulations (such as correct emulsifiers for particular
situations).
Performance
Indicators
Formulation guidelines developed
and distributed.
Evidence that publications produced
by the program are cited in a wide range of literature including patents
and patent applications.
Studies funded that have resulted
in advancing proof of tea tree oil effectiveness for particular uses.
Recognition by product developers
and manufacturers of proof of concept research funded by the program.
Evidence of new product development
activities as a result of contact with the program.
Objective 4:
Fostering communication that increases understanding and thereby encourages
greater use of tea tree oil
Strategies
Develop a database of existing
uses of tea tree oil worldwide including specific products and manufacturers.
Prepare a dossier of existing
tea tree oil research. The dossier should summarise research categorising
efficacy and safety for a range of uses (eg. cosmetic, anti-microbial,
industrial, biocidal, agricultural) and should be made available to researchers
and those involved in product development. Brief, sharp summaries should
also be prepared.
Education of industry segments
as to the availability of research outputs.
Develop a plan and processes
to liaise between the industry, researchers and product manufacturers to
ensure communication of research results, and identification of opportunities
for early-stage research and exploration.
Performance
Indicators
Use, product and manufacturer
database developed.
Tea tree oil R&D dossier
developed and distributed.
Brief summaries of R&D findings
from the program disseminated widely.
Appendix 1:
The R&D Advisory Committee 2005
Ms Pat Bolster (Chair)
Willow Management Pty Ltd
Mr Craig Chapman
Melaleuca Plantations of
Bungawalbyn Pty Ltd
Mr Richard Davis
G.R. Davis Pty Ltd |
Mr Jim Gobert
Unifect International
Mr Steen Jorsal
Novasel Australia Pty Ltd
Dr Roslyn Prinsley
RIRDC |
Appendix
2: RIRDC/ATTIA R&D Expenditure to Date (nominal $)
| Year |
Approved Program Budget
|
Industry Contribution
|
| 1990/91 |
250 000
|
24 563
|
| 1991/92 |
250 000
|
34 405
|
| 1992/93 |
250 000
|
48 050
|
| 1993/94 |
300 000
|
44 000
|
| 1994/95 |
280 000
|
55 906
|
| 1995/96 |
250 000
|
62 500
|
| 1996/97 |
150 000
|
75 000
|
| 1997/98 |
305 550
|
151 850
|
| |
Program Expenditure
|
Industry Contribution
|
| 1998/99 |
375,399
|
172,200
|
| 1999/2000 |
346,393
|
128,956
|
| 2000/01 |
643,075
|
332,306
|
| 2001/02 |
296,669
|
99,212
|
| 2002/03 |
378,314
|
32,549
|
| 2003/04 |
370,440
|
123,144
|
| 2004/05 |
299,254
|
74,942
|
| 2005/6* |
435,000
|
182,435
|
* Expected expenditure and pledged
industry contributions.
Appendix
3: Current and Completed Projects
Projects Funded over the
Period 1998-2005
| Project
No |
Title
|
Start
year |
End
year |
Researcher/Organisation |
Industry
Contributor |
| Safety,
Efficacy and Product Development |
| 1.
UNC-7A |
Tea
tree oil as a topical decolonisation agent for adult inpatients with Methicillin–Resistant
Staphylococcus
aureus (MRSA) |
1998/99 |
2000/01 |
John
Attia, U of Newcastle |
Australian
Bodycare |
| 2.
UWA-80A |
Effects
of tea tree oil on Staphylococcus aureus virulence factors |
2003/04 |
2004/05 |
Tom
Riley, UWA |
Novasel |
| 3.
UWA-43A |
The
anti-inflammatory activity of tea tree oil |
1998/99 |
1999/00 |
Tom
Riley, UWA |
Thursday
Plantation |
| 4.
UF-5A |
The
anti-inflammatory activity of tea tree oil –second stage |
1999/00 |
2000/01 |
John
Finlay–Jones, FU |
Thursday
Plantation |
| 5.
UF-6A |
The
anti-inflammatory and anti itch properties of tea tree oil |
2001/02 |
2001/02 |
John
Finlay–Jones, FU |
Thursday
Plantation |
| 6.
UWA-42A |
Skin
sensitivity testing for tea tree oil |
1998/99 |
1998/99 |
Christine
Carson, UWA |
|
| 7.
UWA-51A |
Skin
sensitivity testing for tea tree oil – second stage |
1999/00 |
1999/00 |
Tom
Riley, UWA |
|
| 8.
UWA-55A |
Antimicrobial
activity of tea tree oil against oral micro-organisms |
2001/02 |
2002/03 |
Tom
Riley, UWA |
Australian
Bodycare |
| 9.
UWA-56A |
Clinical
efficacy of tea tree oil for treating cold sores |
2001/02 |
2001/02 |
Tom
Riley, UWA |
Australian
Bodycare |
| 10.
UWA-50A |
The
anti-fungal activity of tea tree oil |
1999/00 |
2000/01 |
Christine
Carson, UWA |
|
| 11.
UWA-58A |
The
anti-fungal activity of tea tree oil |
2001/02 |
2002/03 |
Tom
Riley, UWA |
Australian
Bodycare |
| 12.
UWA-75A |
Compilation
and review of published and unpublished tea tree oil literature |
2002/03 |
2003/04 |
Tom
Riley, UWA |
|
| 13.
UWA-72A |
Assessing
the in situ efficacy of tea tree oil as a topical antiseptic |
2002/03 |
2004/05 |
Tom
Riley, UWA |
Novasel |
| 14.
UWA-57A |
Multi-centre
randomised clinical trials for tea tree oil products for vaginal infections |
2002/03 |
2002/03 |
Tom
Riley, UWA |
Australian
Bodycare |
| 15.
UWA-40A |
Antiviral
activity of tea tree oil – in vitro and in vivo |
1998/99 |
2000/01 |
Christine
Carson, UWA |
|
| Project
No |
Title
|
Start
year |
End
year |
Researcher/Organisation |
Industry
Contributor |
| 16.
UWA-79A |
Tolerance
of Pseudomonas areaeruginosa to tea tree oil |
2003/04 |
2004/05 |
Christine
Carson, UWA |
Novasel |
| 17.
UF-8A |
Regulation
of immune responses in human skin by tea tree oil |
2001/02 |
2002/03 |
John
Finlay–Jones, FU |
Novasel |
| 18.
SAG-3A |
Evaluation
of tea tree oil as an insecticide in vegetables |
2002/03 |
2002/03 |
Keith
Lewis, Serve Ag BFS |
Serve
Ag
BFS |
| 19.
SAH-1A |
Development
of tea tree/ hydrogel dressings for use in wound care |
2003/04 |
2004/05 |
Gary
Bain |
Rye
Pharmaceuticals |
| 20.
ATT-1A |
Mutagenicity
study |
2004/05 |
2004/05 |
Isabelle
Meyer-Carrive |
ATTIA |
| 21.
MS034-12 |
Review
of the data available on toxicology/safety of tea tree oil |
2003/04 |
2003/04 |
Jesper
Bo-Nielsen |
|
| Sustainable
Production Systems |
| 22.
DAN -151A/199A |
Breeding
and cloning tea tree for greater profitability |
1998/99 |
2004/05 |
John
Doran, CSIRO |
ATTIA |
| 23.
CSF-55A |
Development
of DNA markers for tea tree |
1998/99 |
1999/00 |
John
Doran, CSIRO |
ATTIA |
| 24.
DAQ-252A |
Plant
nutritional survey of the Australian tea tree industry |
1998/99 |
1999/00 |
James
Drinnan, QDPI |
ATTIA |
Appendix
4: Contacts
Australian Tea
Tree Industry Association
Mr Peter Bryant
Phone : 02 66 874 162
Fax : 02 66 875 050
Email : ttree@westnet.com.au
Tea Tree Oil Research and
Development Advisory Committee 2005
Ms Pat Bolster (Chair)
Willow Management Pty Ltd
Ph: 02 6674 2991
Fax: 02 6674 2475
Email: pbolster@ozemail.com.au
Mr Craig Chapman
Melaleuca Plantations of
Bungawalbyn Pty Ltd
Tel: 02 6683 2480
Fax: 02 6683 2329
Email: melplant@nor.com.au
Mr Richard Davis
G.R. Davis Pty Ltd
Tel: 02 9627 4537
Fax: 02 9627 5468
Email: richard@grdavis.com.au
|
Mr Jim Gobert
Unifect International
Ph: 02 9654 0129
Mob: 0402 309 396
Email: jgobert@tpg.com.au
Mr Steen Jorsal
Novasel Australia Pty Ltd
Ph: 07 5522 9346
Fax: 07 5559 0593
Email: sjorsal@novasel.org
Dr Roslyn Prinsley
RIRDC
Ph: 02 6272 5227
Fax: 02 6272 5877
Email: roslyn.prinsley@rirdc.gov.au
|
|
Foreword
